BioSpace News Archive

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced publication of abstract #2501 by the American Society of Clinical Oncology (ASCO). The abstract summarizing interim data from the National Cancer Institute (NCI)-led phase 2 trial has been accepted for oral presentation at the 2021

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William Feehery, Chief Executive Officer, and Andrew Schemick, Chief Financial Officer, will participate in the following virtual investor conferences: William Blair’s 41st Annual Growth Stock Conference Fireside Chat on Tuesday, June 1 st at 11:40 a.m. ET Jefferies Virtual Healthcare Conference Fireside Chat on Friday, June 4 th at 10:00 a.m. ET

via NewMediaWire – Medolife Rx, Inc., a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc., announced that it completed its initial meetings with CONABIOS, the medical ethics committee that oversees all clinical trial programs in the Dominican Republic.

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, reported first quarter 2021 financial results and provided an operational update.

DNA Script, a leading pioneer in enabling enzymatic DNA synthesis on demand, announced the third and final phase of its evaluation program for the SYNTAX System, the world’s first benchtop printer powered by Enzymatic DNA Synthesis technology.

The webinars highlight ways employers, payers, and government programs can improve healthcare affordability and outcomes for underserved populations.

PBI-100 is a topical treatment being developed for people living with mild to moderate psoriasis PBI-100 is a highly-selective tropomyosin receptor kinase (TRK) inhibitor Psoriasis affects more than 120 million people worldwide, nearly eight million in US

Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, today announced that the company will present data from its Phase 2 clinical trial of PEN-221 at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting occurring virtually June 4-8, 2021.

Intensity Therapeutics Announces Two Abstracts to Be Presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for infectious diseases, vaccines, rare diseases, and oncology, is now enrolling UK volunteers into a pivotal Phase III COVID-19 vaccine study.